Vericel VCEL
NASDAQ VCEL
$39.04 -0.04 (-0.10%)
As of: Sep 9, 2026 · 3:20 PM EDT

Vericel (VCEL) Non-Current Deffered Revenue (2016 - 2019)

Vericel's (VCEL) quarterly Non-Current Deffered Revenue came in at $1.9 million in Q2 2019, down 3.01% year-over-year from $2.0 million in Q2 2018, and little changed quarter-over-quarter from $1.9 million in Q1 2019.

Analysis

Vericel (VCEL) Non-Current Deffered Revenue (2016 - 2019) Analysis & Trends

Vericel has disclosed Non-Current Deffered Revenue across 4 years of filings, most recently posting $1.9 million for Q2 2019.

  • In Q2 2019, Non-Current Deffered Revenue fell 3.01% year-over-year to $1.9 million; the TTM figure through Jun 2019 stood at $1.9 million (down 3.01% YoY), while the FY2018 annual figure was $1.7 million, down 19.09% from the prior year.
  • Non-Current Deffered Revenue came in at $1.9 million for Q2 2019 at Vericel, roughly flat from $1.9 million in the prior quarter.
  • In the past five years, Non-Current Deffered Revenue ranged from a high of $2.1 million in Q4 2017 to a low of $900000.0 in Q2 2016.
  • Average Non-Current Deffered Revenue over 4 years is $1.7 million, with a median of $1.7 million recorded in 2016.
  • Year-over-year, Non-Current Deffered Revenue surged 74.11% in 2017 and fell 19.09% in 2018.
  • Over 4 years, Non-Current Deffered Revenue stood at $1.7 million in 2016, then gained by 22.05% to $2.1 million in 2017, then declined by 19.09% to $1.7 million in 2018, then increased by 14.05% to $1.9 million in 2019.
  • Per Business Quant data, the three most recent Non-Current Deffered Revenue figures were $1.9 million in Q2 2019, $1.9 million in Q1 2019, and $1.7 million in Q4 2018.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Non-Current Deffered Revenue (Qtr)
1 Krystal Biotech 10.26 Bn 9.41 Bn 112.79 Mn -
2 CRISPR Therapeutics AG 5.20 Bn 5.20 Bn - -
3 Iovance Biotherapeutics 3.79 Bn 3.49 Bn 55.72 Mn -
4 Legend Biotech 3.68 Bn 2.71 Bn 251.50 Mn -
5 uniQure 3.06 Bn 3.06 Bn 5.49 Mn -
6 Beam Therapeutics 2.68 Bn 2.68 Bn - -
7 Precigen 2.44 Bn 2.44 Bn 52.17 Mn -
8 Sarepta Therapeutics 2.34 Bn 1.55 Bn 251.87 Mn 110.13 Mn
9 Vericel 1.99 Bn 1.83 Bn 56.40 Mn -
10 Taysha Gene Therapies 1.99 Bn 1.99 Bn - -
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2019 1.90 Mn
Mar 31, 2019 1.90 Mn
Dec 31, 2018 1.67 Mn
Sep 30, 2018 1.90 Mn
Jun 30, 2018 1.96 Mn
Mar 31, 2018 1.95 Mn
Dec 31, 2017 2.06 Mn
Sep 30, 2017 1.61 Mn
Jun 30, 2017 1.57 Mn
Mar 31, 2017 1.63 Mn
Dec 31, 2016 1.69 Mn
Sep 30, 2016 1.23 Mn
Jun 30, 2016 900,000.00